迈威生物：关于注射用7MW4911临床试验申请获得国家药品监督管理局和美国FDA受理的公告

Core Viewpoint - Maiwei Biotech announced the acceptance of its clinical trial application for the injectable 7MW4911 by the National Medical Products Administration (NMPA) and the acknowledgment of its IND application by the U.S. Food and Drug Administration (FDA) [2] Group 1 - The company received a formal acceptance notice from NMPA for the clinical trial application of injectable 7MW4911 [2] - The FDA issued an IND Acknowledgment Letter confirming receipt of the IND application for injectable 7MW4911 [2]